NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IGC Stock Alerts $0.44 +0.00 (+0.23%) (As of 09:32 AM ET) Add Compare Share Share Today's Range$0.42▼$0.4450-Day Range N/A52-Week Range$0.25▼$0.91Volume37,965 shsAverage Volume793,447 shsMarket Capitalization$29.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest Get IGC Pharma alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About IGC Pharma Stock (NYSEAMERICAN:IGC)IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesApril 24, 2024 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Now Covered by Analysts at StockNews.comApril 18, 2024 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Coverage Initiated by Analysts at StockNews.comApril 25, 2024 | InvestorPlace (Ad)The #1 Crypto for 20245 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 17, 2024 | msn.comCDC investigating reports of counterfeit or mishandled Botox injections in 9 statesApril 17, 2024 | americanbankingnews.comShort Interest in IGC Pharma, Inc. (NYSEAMERICAN:IGC) Expands By 10.6%April 16, 2024 | benzinga.comIGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated AgitationApril 16, 2024 | stockhouse.comIGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week TwoApril 16, 2024 | finance.yahoo.comIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoApril 25, 2024 | InvestorPlace (Ad)The #1 Crypto for 20245 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 9, 2024 | barrons.comIGC Pharma Inc.April 9, 2024 | businesswire.comIGC Pharma Adds Advisor in Artificial IntelligenceApril 2, 2024 | benzinga.comIGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's ResearchMarch 28, 2024 | msn.comAll About Kyle Richards' Mom Kathleen RichardsMarch 26, 2024 | businesswire.comIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockMarch 20, 2024 | msn.comAlzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To PlaceboMarch 20, 2024 | msn.comEXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early SuccessMarch 20, 2024 | finance.yahoo.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationMarch 20, 2024 | businesswire.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's AgitationMarch 20, 2024 | businesswire.comIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024March 12, 2024 | finance.yahoo.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineMarch 12, 2024 | businesswire.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's PipelineFebruary 28, 2024 | marketwatch.comIGC Pharma Sees Positive Memory Function Data in Preclinical Study of Alzheimer's Disease DrugFebruary 28, 2024 | finance.yahoo.comPromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelFebruary 23, 2024 | finance.yahoo.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price TargetFebruary 23, 2024 | businesswire.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetFebruary 19, 2024 | benzinga.comIGC Pharma Stock (AMEX:IGC) Dividends: History, Yield and DatesFebruary 19, 2024 | benzinga.comIGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid LossesSee More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,510,000.00 Net Margins-1,163.24% Pretax Margin-1,163.24% Return on Equity-110.37% Return on Assets-93.34% Debt Debt-to-Equity Ratio0.02 Current Ratio1.85 Quick Ratio0.86 Sales & Book Value Annual Sales$910,000.00 Price / Sales32.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.57Miscellaneous Outstanding Shares66,810,000Free Float54,119,000Market Cap$29.40 million OptionableNot Optionable Beta1.71 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 65)President, CEO & Director Comp: $705kMs. Claudia Grimaldi (Age 53)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $245kMr. Rohit Goel (Age 30)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsNRx PharmaceuticalsNASDAQ:NRXPDaré BioscienceNASDAQ:DAREHelix BioPharmaOTCMKTS:HBPCFAprea TherapeuticsNASDAQ:APREImmunoPrecise AntibodiesNASDAQ:IPAView All Competitors IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed in 2024? IGC Pharma's stock was trading at $0.3446 at the start of the year. Since then, IGC shares have increased by 27.4% and is now trading at $0.4390. View the best growth stocks for 2024 here. Are investors shorting IGC Pharma? IGC Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 938,800 shares, an increase of 10.6% from the March 15th total of 848,500 shares. Based on an average daily volume of 740,100 shares, the short-interest ratio is presently 1.3 days. View IGC Pharma's Short Interest. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its quarterly earnings results on Wednesday, February, 14th. The construction company reported ($0.09) earnings per share for the quarter. The construction company had revenue of $0.20 million for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative trailing twelve-month return on equity of 110.37%. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO). How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:IGC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
